A
Anne E. Borgman-Hagey
Researcher at Exelixis
Publications - 8
Citations - 2576
Anne E. Borgman-Hagey is an academic researcher from Exelixis. The author has contributed to research in topics: Cabozantinib & Sorafenib. The author has an hindex of 7, co-authored 8 publications receiving 1823 citations. Previous affiliations of Anne E. Borgman-Hagey include University of California, San Francisco.
Papers
More filters
Journal ArticleDOI
Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
Ghassan K. Abou-Alfa,Tim Meyer,Ann-Lii Cheng,Anthony B. El-Khoueiry,Lorenza Rimassa,Baek Yeol Ryoo,Irfan Cicin,Philippe Merle,Yen-Hsun Chen,Joong-Won Park,Jean-Frédéric Blanc,Luigi Bolondi,Heinz Josef Klümpen,Heinz Josef Klümpen,Stephen L. Chan,Vittorina Zagonel,Tiziana Pressiani,Min Hee Ryu,Alan P. Venook,Alan P. Venook,Colin Hessel,Anne E. Borgman-Hagey,Gisela Schwab,Robin Kate Kelley +23 more
TL;DR: Treatment with cabozantinib resulted in longer overall survival and progression‐free survival than placebo among patients with previously treated advanced hepatocellular carcinoma, and the rate of high‐grade adverse events in the cabozaninib group was approximately twice that observed in the placebo group.
Journal ArticleDOI
Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma
Toni K. Choueiri,Bernard Escudier,Thomas Powles,Paul N. Mainwaring,Brian I. Rini,Frede Donskov,Hans J. Hammers,Thomas E. Hutson,Jae-Lyun Lee,Katriina Peltola,Bruce J. Roth,Georg A. Bjarnason,Lajos Géczi,Bhumsuk Keam,Pablo Maroto,Daniel Y.C. Heng,Manuela Schmidinger,Philip W. Kantoff,Anne E. Borgman-Hagey,Colin Hessel,Christian Scheffold,Gisela Schwab,Nizar M. Tannir,Robert J. Motzer +23 more
TL;DR: Progression-free survival was longer with cabozantinib than with everolimus among patients with renal-cell carcinoma that had progressed after VEGFR-targeted therapy.
Journal ArticleDOI
Cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC) who have received prior sorafenib: Results from the randomized phase III CELESTIAL trial.
Ghassan K. Abou-Alfa,Tim Meyer,Ann-Lii Cheng,Anthony B. El-Khoueiry,Lorenza Rimassa,Baek-Yeol Ryoo,Irfan Cicin,Philippe Merle,Joong-Won Park,Jean-Frédéric Blanc,Luigi Bolondi,Heinz-Josef Klümpen,Stephen L. Chan,Vincenzo Dadduzio,Colin Hessel,Anne E. Borgman-Hagey,Gisela Schwab,Robin Kate Kelley +17 more
TL;DR: This phase 3 trial evaluated C vs P in previously treated pts with advanced HCC and found that C, an inhibitor of MET, VEGFR, and AXL has previously shown clinical activity in pts withAdvanced HCC.
Journal ArticleDOI
Phase 3 randomized, double-blind, controlled study of cabozantinib (XL184) versus placebo in subjects with hepatocellular carcinoma who have received prior sorafenib (CELESTIAL; NCT01908426).
Ghassan K. Abou-Alfa,Ann-Lii Cheng,Tim Meyer,Anthony B. El-Khoueiry,Masafumi Ikeda,Hoo Geun Chun,Sandrine Faivre,Junji Furuse,Jennifer J. Knox,Takuji Okusaka,Jerry Ping,Anne E. Borgman-Hagey,Robin Kate Kelley +12 more
TL;DR: This phase 3, randomized, double-blind study evaluates the efficacy and safety of cabozantinib compared with placebo in subjects with advanced HCC previously treated with sorafenib and have progressed following 1-2 prior systemic treatments for HCC.
Journal ArticleDOI
Outcomes based on plasma biomarkers for the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (aHCC)
Lorenza Rimassa,Robin Katie Kelley,Tim Meyer,Baek-Yeol Ryoo,Philippe Merle,Joong-Won Park,Jean-Frédéric Blanc,H. Y. Lim,A. Tran,Anne E. Borgman-Hagey,Douglas O. Clary,E. Wang,A-L Cheng,Anthony B. El-Khoueiry,Ghassan K. Abou-Alfa +14 more